Clinical distribution and drug resistance analysis of Acinetobacter baumannii in a hospital from 2018 to 2022
Objective The infection of Acinetobacter baumannii and its resistance characteristics were analyzed to provide reference for rational clinical use of antibiotics and prevent nosocomial infection.Methods Acinetobacter baumannii was isolated from outpatient and inpatient bacterial culture samples and drug resistance was analyzed from 2018 to 2022.Results From 2018 to 2022,a total of 14 027 clinical isolates were collected,among which 864 Acinetobacter baumannii were isolated,with a detection rate of 6.16％(864/14 027).A total of 407 carbapenem-resistant Acinetobacter baumannii(CRAB)strains were detected,accounting for 47.11％(407/864),and 457 carbapenem-susceptible Acinetobacter baumannii(CSAB)strains,accounting for 52.89％(457/864).The main isolated samples of Acinetobacter baumannii were mainly sputum,accounting for 90.05％(778/864).The main department which Acinetobacter baumannii was isolated was the intensive care unit(ICU),accounting for 33.33％(288/864),followed by respiratory medicine,accounting for 16.09％(139/864).Of the 14 antibiotics tested,the highest Acinetobacter baumannii resistance were piperacillin/tazobactam(54.04％),followed by ciprofloxacin(50.64％),ticab/clavulanate(47.51％)and levofloxacin(45.81％);CRAB resistance was pib/tazobactam/clavulanate,both 100.00％,followed by ciprofloxacin(99.74％),levofloxacin(89.42％)and tobramycin(88.50％).The antimicrobial agents with the highest resistance to CSAB were compound sulfamethoazole(6.50％),followed by ciprofloxacin(6.40％),levofloxacin(6.10％),and piperacillin/tazobactam(5.80％).Acinetobacter baumannii,CRAB,and CSAB were not resistant to polymyxin,cefoperazone/sulbactam,and tigecycline,which showed 100.00％susceptible to all three antimicrobial agents.Conclusion Acinetobacter baumannii had serious resistance to a variety of antimicrobial drugs,especially CRAB,which should be used and standardized to inhibit the production of drug-resistant strains and provide scientific reference basis for clinical infection prevention and control.
Acinetobacter baumanniiCarbapenem-resistant Acinetobacter baumanniiAntibacterial drug
NETL
NSTL
万方数据
